Efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial...

Clinical study on influencing factors to stability of warfarin anticoagulant therapy in patients with persistent atrial fibrillation

LUO Xiao, C Ling - J Clin Cardiol, 2022 - en.whuhzzs.com

Clinical study on influencing factors to stability of warfarin anticoagulant therapy in patients
with persistent atrial fibrillation Homepage Journals 1.{{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} …

被引用次数：2 相关文章所有 3 个版本

[PDF] core.ac.uk

[PDF][PDF] Impact of Obesity on Atrial Fibrillation Pathogenesis and Treatment Options

M Kalla, AP Holmes, C O'Shea, D Pavlovic - 2023 - core.ac.uk

Atrial fibrillation (AF) is the most common cardiac arrhythmia. AF increases the risk of stroke,
heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both …

The “Obesity Paradox” and the use of NOAC

R Bottino, A Carbone, B Liccardo, P Golino… - … : From Pharmacology to …, 2021 - Springer

Obesity is a worldwide health problem at increasing incidence associated with high
morbidity and mortality. Although obesity increases patients' cardiovascular (CV) risk, more …

被引用次数：1 相关文章所有 3 个版本

[PDF] cvs.org.ua

Non-Vitamin K Antagonist Oral Anticoagulants in Differentiated Approach to the Use in Cardiological Practice: Literature Review

LA Vozniuk, OV Dzekan, SO Siromakha - Ukrainian Journal of …, 2023 - cvs.org.ua

Non-vitamin K antagonist oral anticoagulants (novel oral anticoagulants, NOACs) are
important pharmaceuticals for prevention of stroke and systemic embolism in non-valvular …

[PDF][PDF] Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction

BSPPH Kumar, S George, SMVGGN Gupta, K Makineni… - 2022 - academia.edu

Non-vitamin K antagonist oral anticoagulants (NOACs) are a new class of anticoagulant
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …

Comparison of Direct Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Obese or Overweight Patients: A Retrospective …

JC Cook, TE Wiczer, AT Gerlach… - Journal of …, 2021 - search.ebscohost.com

BACKGROUND: Direct-acting oral anticoagulants (DOACs) represent an alternative to
vitamin K antagonists in the treatment of venous thromboembolism (VTE); however …

被引用次数：1 相关文章

[PDF] academia.edu